SAB Biotherapeutics’ SAB-185 moves to Phase 3 trial for Covid-19 treatment
Advancement to Phase 3 is a major milestone for SAB’s unique DiversitAb immunotherapy platform that produces fully human polyclonal antibodies without human donors
Advancement to Phase 3 is a major milestone for SAB’s unique DiversitAb immunotherapy platform that produces fully human polyclonal antibodies without human donors
It paves way for the launch of Selumetinib 10 mg & 25 mg capsule in India, subject to the receipt of related statutory approvals and licenses
The company will leverage existing hospital and clinic partners’ infrastructure to build specialised `Experience Centres’ and facilitate a seamless, end-to-end secondary care surgery delivery. It will also offer healthcare financing
The pivotal Phase 3 trial achieved all primary endpoints, demonstrating non-inferiority to a leading U.S.-licensed quadrivalent influenza vaccine
Seed Spark is an online entrepreneurship program offered by Stanford Seed. Health Sensei emerged as a winner competing with 86 startups from their May-Aug 2021 graduating cohort
The company is the Clinical Research Organisation of Caplin Point Laboratories
CuraTeQ Biologics is on track for filing a second oncology biosimilar
Three new molecular diagnostic test panels for influenza and other common respiratory illnesses can be run together or alone using one patient sample
The NanoDrop Eight simultaneously evaluates eight samples in 20 seconds or less and the instrument can also measure high-concentration samples of up to 200 absorbance units without dilution
Emergency Use Authorisation (EUA) is granted for individuals 65 years of age and older, and individuals ages 18 through 64 within certain high-risk groups
Subscribe To Our Newsletter & Stay Updated